Disclosure of transactions in own shares on November 14 to November 18, 2022 Read more about Disclosure of transactions in own shares on November 14 to November 18, 2022
SII : SII entre en négociations exclusives avec METANEXT en vue de l’acquisition de 100% du capital Read more about SII : SII entre en négociations exclusives avec METANEXT en vue de l’acquisition de 100% du capital
GBL - Transactions on GBL shares 21-11-2022 Read more about GBL - Transactions on GBL shares 21-11-2022
Total number of shares and voting rights in the share capital as of October 31, 2022 Read more about Total number of shares and voting rights in the share capital as of October 31, 2022
GBL launches EUR 500 million bonds exchangeable into existing shares of Pernod Ricard due 2025 Read more about GBL launches EUR 500 million bonds exchangeable into existing shares of Pernod Ricard due 2025
AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s Disease Read more about AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s Disease
GEVELOT S.A.: Weekly report of share buyback November 21, 2022 Read more about GEVELOT S.A.: Weekly report of share buyback November 21, 2022
MEDESIS PHARMA ANNOUNCES THE CONSTITUTION OF A PERMANENT SCIENTIFIC ADVISORY BOARD OF EXPERTS IN NEURODEGENERATIVE DISEASES Read more about MEDESIS PHARMA ANNOUNCES THE CONSTITUTION OF A PERMANENT SCIENTIFIC ADVISORY BOARD OF EXPERTS IN NEURODEGENERATIVE DISEASES
TotalEnergies SE: Disclosure of Transactions in Own Shares Read more about TotalEnergies SE: Disclosure of Transactions in Own Shares
OSE Immunotherapeutics Announces Publication of Peer-Reviewed Data on CLEC-1, its Novel Myeloid Immune Checkpoint in ‘Science Advances’ Read more about OSE Immunotherapeutics Announces Publication of Peer-Reviewed Data on CLEC-1, its Novel Myeloid Immune Checkpoint in ‘Science Advances’